Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $29.70.

Several equities analysts recently issued reports on the company. UBS Group raised their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. TD Cowen boosted their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Finally, KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Shiv O’Neill acquired 3,998 shares of Elanco Animal Health stock in a transaction on Tuesday, August 18th. The shares were purchased at an average cost of $23.58 per share, with a total value of $94,272.84. Following the completion of the purchase, the insider owned 87,832 shares in the company, valued at $2,071,078.56. The trade was a 4.77% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Michael Harrington bought 5,000 shares of the stock in a transaction on Wednesday, August 12th. The shares were acquired at an average cost of $21.82 per share, with a total value of $109,100.00. Following the acquisition, the director directly owned 131,451 shares in the company, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 63,198 shares of company stock valued at $1,473,109 over the last three months. 1.14% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Anchor Investment Management LLC acquired a new position in Elanco Animal Health in the second quarter valued at about $29,000. Integrated Wealth Concepts LLC acquired a new position in shares of Elanco Animal Health during the 2nd quarter worth about $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Elanco Animal Health during the 2nd quarter worth about $38,000. Root Financial Partners LLC increased its stake in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares during the last quarter. Finally, Bessemer Group Inc. increased its stake in shares of Elanco Animal Health by 33.2% in the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after acquiring an additional 525 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Stock Up 2.0%

NYSE:ELAN opened at $22.21 on Friday. The stock’s fifty day moving average price is $23.75 and its two-hundred day moving average price is $23.71. Elanco Animal Health has a 52-week low of $19.40 and a 52-week high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The company has a market cap of $11.10 billion, a price-to-earnings ratio of -54.18, a P/E/G ratio of 1.58 and a beta of 1.70.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the company earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts anticipate that Elanco Animal Health will post 1.13 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio includes veterinary pharmaceuticals, vaccines, parasiticides, nutritional products and other solutions designed to prevent and treat disease, improve animal well-being and support livestock productivity.

For companion animals, Elanco offers products addressing pain, osteoarthritis, dermatological conditions, infectious diseases and flea, tick and intestinal parasite control.